Pharmaceutical industry
Novo Nordisk strokes 9,000 jobs – pressure at weight loss injections
The Danish pharmaceutical company struggles with a fading boom in the spraying injections. The shares of the former stock market favorite have fallen strongly. Novo Nordisk now takes hard measures.
The Danish pharmaceutical company Novo Nordisk starts the red pencil in view of the sharp competition for weight loss. 9,000 jobs worldwide would be deleted, the company, known primarily for its weight loss injection, announced in Bagsvaerd near Copenhagen. That is 11.5 percent of the workforce. More than half of the jobs – around 5,000 jobs – are to be lost in the Denmark home market.
It was initially not known whether jobs will be canceled in Germany, where Novo Nordisk has its headquarters in Mainz. It is a global transformation, said a spokeswoman, “and every country, every location and every region will be affected differently”. The plans are not yet finalized.
With the job reduction, Novo Nordisk reacted to the increasing competitive pressure on the market for weight loss preparations, in particular by the US competitor Eli Lilly, who is successful with the Zepbound competitive preparation. Eli Lilly also wants to buy in Europe and invests a billion-dollar amount for a new work in Alzey, Rhineland-Palatinate.
“Our markets continue to develop, especially in the area of obesity, since the competition increases there and the consumer is coming to the fore more,” said Novo-Northisk boss Mike Dustdar. “Our company also has to develop”.
Former stock market favorite under pressure
The aim is to set up the company slimmer and accelerate decisions. For example, the group is to be geared towards growth opportunities in the field of diabetes and obesity. The forecast for the profit this year was significantly reduced.
Novo Nordisk puts the costs for the reorganization at eight billion Danish crowns (EUR 1.07 billion). The management wants to save just as much from 2026.
Novo Nordisk had occurred to Europe’s most valuable stock market group in the boom around weight loss medication in 2024. However, the company is now difficult for the company to make competition with Eli Lilly, especially in the United States. In the sight of one year, the Novo Nordisk share has lost around 60 percent of value.
dpa
Source: Stern
